TW200938221A - Protein formulations and methods of making same - Google Patents

Info

Publication number

TW200938221A

TW200938221A TW097146498A TW97146498A TW200938221A TW 200938221 A TW200938221 A TW 200938221A TW 097146498 A TW097146498 A TW 097146498A TW 97146498 A TW97146498 A TW 97146498A TW 200938221 A TW200938221 A TW 200938221A

Authority

TW

Taiwan

Prior art keywords

formulation

protein

concentration

solution

antibody

Prior art date

2007-11-30

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000623 proteins and genes Proteins 0.000 title claims abstract description 497
• 102000004169 proteins and genes Human genes 0.000 title claims abstract description 490
• 239000000203 mixture Substances 0.000 title claims abstract description 358
• 238000009472 formulation Methods 0.000 title claims abstract description 310
• 238000000034 method Methods 0.000 title claims abstract description 182
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 341
• 229910001868 water Inorganic materials 0.000 claims abstract description 190
• 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 134
• 239000013011 aqueous formulation Substances 0.000 claims abstract description 97
• 239000000243 solution Substances 0.000 claims description 259
• 239000003814 drug Substances 0.000 claims description 100
• 238000011026 diafiltration Methods 0.000 claims description 69
• 239000000427 antigen Substances 0.000 claims description 66
• 239000012460 protein solution Substances 0.000 claims description 66
• 108091007433 antigens Proteins 0.000 claims description 65
• 102000036639 antigens Human genes 0.000 claims description 65
• 230000035699 permeability Effects 0.000 claims description 63
• 239000012634 fragment Substances 0.000 claims description 61
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 32
• 229930195725 Mannitol Natural products 0.000 claims description 32
• 239000000594 mannitol Substances 0.000 claims description 32
• 235000010355 mannitol Nutrition 0.000 claims description 32
• 230000001225 therapeutic effect Effects 0.000 claims description 31
• 239000007924 injection Substances 0.000 claims description 30
• 238000002347 injection Methods 0.000 claims description 30
• 238000004519 manufacturing process Methods 0.000 claims description 29
• 239000003795 chemical substances by application Substances 0.000 claims description 28
• 239000007788 liquid Substances 0.000 claims description 25
• 108010050904 Interferons Proteins 0.000 claims description 23
• 102000014150 Interferons Human genes 0.000 claims description 23
• 229940079322 interferon Drugs 0.000 claims description 22
• -1 mannitol or sterol Chemical class 0.000 claims description 21
• 230000002378 acidificating effect Effects 0.000 claims description 20
• 210000004027 cell Anatomy 0.000 claims description 20
• 108010081589 Becaplermin Proteins 0.000 claims description 19
• 239000004094 surface-active agent Substances 0.000 claims description 19
• 229960002964 adalimumab Drugs 0.000 claims description 18
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 239000012141 concentrate Substances 0.000 claims description 15
• 239000000047 product Substances 0.000 claims description 15
• 229960005267 tositumomab Drugs 0.000 claims description 15
• 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims description 11
• HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 claims description 11
• 229960004787 becaplermin Drugs 0.000 claims description 11
• 239000007853 buffer solution Substances 0.000 claims description 11
• 238000005119 centrifugation Methods 0.000 claims description 11
• 235000013601 eggs Nutrition 0.000 claims description 11
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 10
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 10
• 230000004071 biological effect Effects 0.000 claims description 10
• 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 10
• 238000000338 in vitro Methods 0.000 claims description 10
• 229960001972 panitumumab Drugs 0.000 claims description 10
• 229960004641 rituximab Drugs 0.000 claims description 10
• 241000894007 species Species 0.000 claims description 10
• 229960003824 ustekinumab Drugs 0.000 claims description 10
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 9
• 108010019673 Darbepoetin alfa Proteins 0.000 claims description 8
• 108010074604 Epoetin Alfa Proteins 0.000 claims description 8
• 108010008165 Etanercept Proteins 0.000 claims description 8
• 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims description 8
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
• 229930006000 Sucrose Natural products 0.000 claims description 8
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 8
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 8
• 108010017271 denileukin diftitox Proteins 0.000 claims description 8
• 108010067396 dornase alfa Proteins 0.000 claims description 8
• 108010089296 galsulfase Proteins 0.000 claims description 8
• 102000045921 human GAA Human genes 0.000 claims description 8
• 108010072166 idursulfase Proteins 0.000 claims description 8
• 238000001727 in vivo Methods 0.000 claims description 8
• 239000004615 ingredient Substances 0.000 claims description 8
• 239000002953 phosphate buffered saline Substances 0.000 claims description 8
• 229920005862 polyol Polymers 0.000 claims description 8
• 150000003077 polyols Chemical class 0.000 claims description 8
• 229940107568 pulmozyme Drugs 0.000 claims description 8
• 108010084837 rasburicase Proteins 0.000 claims description 8
• 229940116157 regranex Drugs 0.000 claims description 8
• 108010051412 reteplase Proteins 0.000 claims description 8
• 108010017584 romiplostim Proteins 0.000 claims description 8
• 239000005720 sucrose Substances 0.000 claims description 8
• 108010029961 Filgrastim Proteins 0.000 claims description 7
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 7
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 7
• 108010078049 Interferon alpha-2 Proteins 0.000 claims description 7
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 7
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 7
• 229930182558 Sterol Natural products 0.000 claims description 7
• 239000007864 aqueous solution Substances 0.000 claims description 7
• 229940048921 humira Drugs 0.000 claims description 7
• 229960000598 infliximab Drugs 0.000 claims description 7
• 108010010648 interferon alfacon-1 Proteins 0.000 claims description 7
• 108010046821 oprelvekin Proteins 0.000 claims description 7
• 108010044644 pegfilgrastim Proteins 0.000 claims description 7
• 239000012466 permeate Substances 0.000 claims description 7
• 238000000746 purification Methods 0.000 claims description 7
• 108010074523 rimabotulinumtoxinB Proteins 0.000 claims description 7
• 150000003432 sterols Chemical class 0.000 claims description 7
• 235000003702 sterols Nutrition 0.000 claims description 7
• 241000196324 Embryophyta Species 0.000 claims description 6
• 108010005716 Interferon beta-1a Proteins 0.000 claims description 6
• 229960001743 golimumab Drugs 0.000 claims description 6
• 229940038850 rebif Drugs 0.000 claims description 6
• 239000003381 stabilizer Substances 0.000 claims description 6
• 238000007920 subcutaneous administration Methods 0.000 claims description 6
• 229940099073 xolair Drugs 0.000 claims description 6
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
• 101710117542 Botulinum neurotoxin type A Proteins 0.000 claims description 5
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 5
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
• XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 claims description 5
• 229960000446 abciximab Drugs 0.000 claims description 5
• 229960002459 alefacept Drugs 0.000 claims description 5
• 229960000548 alemtuzumab Drugs 0.000 claims description 5
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
• 229950005725 arcitumomab Drugs 0.000 claims description 5
• 229940120638 avastin Drugs 0.000 claims description 5
• 229960004669 basiliximab Drugs 0.000 claims description 5
• 229960000397 bevacizumab Drugs 0.000 claims description 5
• 229940089093 botox Drugs 0.000 claims description 5
• 229940112129 campath Drugs 0.000 claims description 5
• 229940034605 capromab pendetide Drugs 0.000 claims description 5
• 229960003115 certolizumab pegol Drugs 0.000 claims description 5
• 229960005395 cetuximab Drugs 0.000 claims description 5
• 229940090100 cimzia Drugs 0.000 claims description 5
• 239000002577 cryoprotective agent Substances 0.000 claims description 5
• 229960002806 daclizumab Drugs 0.000 claims description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
• 229960002224 eculizumab Drugs 0.000 claims description 5
• 229940082789 erbitux Drugs 0.000 claims description 5
• 229940022353 herceptin Drugs 0.000 claims description 5
• 229950007354 imciromab Drugs 0.000 claims description 5
• 238000011068 loading method Methods 0.000 claims description 5
• 229960003816 muromonab-cd3 Drugs 0.000 claims description 5
• 239000002736 nonionic surfactant Substances 0.000 claims description 5
• 229960000470 omalizumab Drugs 0.000 claims description 5
• 229940029358 orthoclone okt3 Drugs 0.000 claims description 5
• 229960000402 palivizumab Drugs 0.000 claims description 5
• 229940067082 pentetate Drugs 0.000 claims description 5
• 229940116176 remicade Drugs 0.000 claims description 5
• 229940107685 reopro Drugs 0.000 claims description 5
• 229940115586 simulect Drugs 0.000 claims description 5
• 229940055944 soliris Drugs 0.000 claims description 5
• 239000007921 spray Substances 0.000 claims description 5
• 150000005846 sugar alcohols Chemical class 0.000 claims description 5
• 229940036185 synagis Drugs 0.000 claims description 5
• 229960000575 trastuzumab Drugs 0.000 claims description 5
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
• 108010024976 Asparaginase Proteins 0.000 claims description 4
• 102000015790 Asparaginase Human genes 0.000 claims description 4
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 4
• 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 4
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 4
• 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims description 4
• 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 4
• 108010005714 Interferon beta-1b Proteins 0.000 claims description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
• 108091000080 Phosphotransferase Proteins 0.000 claims description 4
• 108010039185 Tenecteplase Proteins 0.000 claims description 4
• GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 4
• 229960003697 abatacept Drugs 0.000 claims description 4
• 229940099550 actimmune Drugs 0.000 claims description 4
• 229940099983 activase Drugs 0.000 claims description 4
• 108010056760 agalsidase beta Proteins 0.000 claims description 4
• 108700025316 aldesleukin Proteins 0.000 claims description 4
• 229960005310 aldesleukin Drugs 0.000 claims description 4
• 229940022705 aldurazyme Drugs 0.000 claims description 4
• 229960004593 alglucosidase alfa Drugs 0.000 claims description 4
• 229960003318 alteplase Drugs 0.000 claims description 4
• 239000003708 ampul Substances 0.000 claims description 4
• 239000003963 antioxidant agent Substances 0.000 claims description 4
• 229940115115 aranesp Drugs 0.000 claims description 4
• 229940094361 arcalyst Drugs 0.000 claims description 4
• 229940009098 aspartate Drugs 0.000 claims description 4
• 229940021459 betaseron Drugs 0.000 claims description 4
• 229940088949 cinryze Drugs 0.000 claims description 4
• 108010084052 continuous erythropoietin receptor activator Proteins 0.000 claims description 4
• 229960005029 darbepoetin alfa Drugs 0.000 claims description 4
• 229960002923 denileukin diftitox Drugs 0.000 claims description 4
• 229940056176 drotrecogin alfa Drugs 0.000 claims description 4
• 108010008250 drotrecogin alfa activated Proteins 0.000 claims description 4
• 229940012882 elaprase Drugs 0.000 claims description 4
• 229940053603 elitek Drugs 0.000 claims description 4
• 229940073038 elspar Drugs 0.000 claims description 4
• 229940073621 enbrel Drugs 0.000 claims description 4
• 229960003388 epoetin alfa Drugs 0.000 claims description 4
• 229940089118 epogen Drugs 0.000 claims description 4
• 229960000403 etanercept Drugs 0.000 claims description 4
• 229940014516 fabrazyme Drugs 0.000 claims description 4
• 229960005390 galsulfase Drugs 0.000 claims description 4
• 235000012907 honey Nutrition 0.000 claims description 4
• 102000044507 human SERPING1 Human genes 0.000 claims description 4
• 229960002396 idursulfase Drugs 0.000 claims description 4
• 239000007943 implant Substances 0.000 claims description 4
• 229940090438 infergen Drugs 0.000 claims description 4
• 108010042414 interferon gamma-1b Proteins 0.000 claims description 4
• 238000007912 intraperitoneal administration Methods 0.000 claims description 4
• 229940065638 intron a Drugs 0.000 claims description 4
• 229940065223 kepivance Drugs 0.000 claims description 4
• 229940054136 kineret Drugs 0.000 claims description 4
• 229960002486 laronidase Drugs 0.000 claims description 4
• 229940029238 mircera Drugs 0.000 claims description 4
• 239000003607 modifier Substances 0.000 claims description 4
• 229940112646 myobloc Drugs 0.000 claims description 4
• 229940103023 myozyme Drugs 0.000 claims description 4
• 229940068704 naglazyme Drugs 0.000 claims description 4
• 229940071846 neulasta Drugs 0.000 claims description 4
• 229940082926 neumega Drugs 0.000 claims description 4
• 229940029345 neupogen Drugs 0.000 claims description 4
• 229940100027 ontak Drugs 0.000 claims description 4
• 229960002404 palifermin Drugs 0.000 claims description 4
• 229940002988 pegasys Drugs 0.000 claims description 4
• 108010092853 peginterferon alfa-2a Proteins 0.000 claims description 4
• 102000020233 phosphotransferase Human genes 0.000 claims description 4
• 229960000424 rasburicase Drugs 0.000 claims description 4
• 229940116243 retavase Drugs 0.000 claims description 4
• 229960002917 reteplase Drugs 0.000 claims description 4
• 108010046141 rilonacept Proteins 0.000 claims description 4
• 229960001886 rilonacept Drugs 0.000 claims description 4
• 229960004262 romiplostim Drugs 0.000 claims description 4
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 4
• 229940113038 tnkase Drugs 0.000 claims description 4
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 3
• 102100039350 Interferon alpha-7 Human genes 0.000 claims description 3
• 102100030694 Interleukin-11 Human genes 0.000 claims description 3
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
• 208000007541 Preleukemia Diseases 0.000 claims description 3
• 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 3
• 229960004238 anakinra Drugs 0.000 claims description 3
• 230000003078 antioxidant effect Effects 0.000 claims description 3
• 229960001776 edrecolomab Drugs 0.000 claims description 3
• 229960004177 filgrastim Drugs 0.000 claims description 3
• 229960003358 interferon alfacon-1 Drugs 0.000 claims description 3
• 238000007918 intramuscular administration Methods 0.000 claims description 3
• 238000001990 intravenous administration Methods 0.000 claims description 3
• 210000004962 mammalian cell Anatomy 0.000 claims description 3
• 229960001840 oprelvekin Drugs 0.000 claims description 3
• 229940035567 orencia Drugs 0.000 claims description 3
• HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims description 3
• 229960001373 pegfilgrastim Drugs 0.000 claims description 3
• 230000003204 osmotic effect Effects 0.000 claims description 2
• 210000002307 prostate Anatomy 0.000 claims 3
• MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 claims 1
• 229940122601 Esterase inhibitor Drugs 0.000 claims 1
• 240000007594 Oryza sativa Species 0.000 claims 1
• 235000007164 Oryza sativa Nutrition 0.000 claims 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
• 239000004067 bulking agent Substances 0.000 claims 1
• 239000007933 dermal patch Substances 0.000 claims 1
• 239000002329 esterase inhibitor Substances 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 238000002386 leaching Methods 0.000 claims 1
• 235000009566 rice Nutrition 0.000 claims 1
• 239000003053 toxin Substances 0.000 claims 1
• 231100000765 toxin Toxicity 0.000 claims 1
• 235000018102 proteins Nutrition 0.000 description 424
• 101100026709 Mus musculus Nprl3 gene Proteins 0.000 description 140
• 239000008215 water for injection Substances 0.000 description 135
• 239000000523 sample Substances 0.000 description 100
• 229940079593 drug Drugs 0.000 description 93
• 238000004458 analytical method Methods 0.000 description 70
• 238000001542 size-exclusion chromatography Methods 0.000 description 57
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 54
• 238000011282 treatment Methods 0.000 description 50
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 41
• 238000002296 dynamic light scattering Methods 0.000 description 41
• 238000004255 ion exchange chromatography Methods 0.000 description 40
• 239000000872 buffer Substances 0.000 description 39
• 238000009295 crossflow filtration Methods 0.000 description 35
• 239000000178 monomer Substances 0.000 description 29
• 239000002609 medium Substances 0.000 description 27
• 239000011780 sodium chloride Substances 0.000 description 27
• 238000000889 atomisation Methods 0.000 description 25
• 238000003860 storage Methods 0.000 description 24
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
• 239000012615 aggregate Substances 0.000 description 22
• 238000005325 percolation Methods 0.000 description 22
• 206010057190 Respiratory tract infections Diseases 0.000 description 21
• 238000005516 engineering process Methods 0.000 description 21
• 238000002474 experimental method Methods 0.000 description 21
• 150000003839 salts Chemical class 0.000 description 20
• 239000012901 Milli-Q water Substances 0.000 description 19
• 239000002253 acid Substances 0.000 description 19
• 230000008859 change Effects 0.000 description 19
• 238000011049 filling Methods 0.000 description 19
• 238000005259 measurement Methods 0.000 description 19
• 230000009467 reduction Effects 0.000 description 19
• 230000008569 process Effects 0.000 description 18
• 239000000443 aerosol Substances 0.000 description 17
• 239000000306 component Substances 0.000 description 17
• 239000012528 membrane Substances 0.000 description 17
• 108090000765 processed proteins & peptides Proteins 0.000 description 16
• 238000000108 ultra-filtration Methods 0.000 description 16
• 235000001014 amino acid Nutrition 0.000 description 15
• 229940024606 amino acid Drugs 0.000 description 14
• 150000001413 amino acids Chemical class 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 239000000126 substance Substances 0.000 description 14
• 108060003951 Immunoglobulin Proteins 0.000 description 13
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
• 230000002776 aggregation Effects 0.000 description 13
• 238000004220 aggregation Methods 0.000 description 13
• 238000000502 dialysis Methods 0.000 description 13
• 238000010790 dilution Methods 0.000 description 13
• 239000012895 dilution Substances 0.000 description 13
• 230000000694 effects Effects 0.000 description 13
• 238000007710 freezing Methods 0.000 description 13
• 230000008014 freezing Effects 0.000 description 13
• 102000018358 immunoglobulin Human genes 0.000 description 13
• 239000000825 pharmaceutical preparation Substances 0.000 description 13
• 238000012545 processing Methods 0.000 description 13
• 238000005070 sampling Methods 0.000 description 13
• 239000004695 Polyether sulfone Substances 0.000 description 12
• 238000010521 absorption reaction Methods 0.000 description 12
• 239000000654 additive Substances 0.000 description 12
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
• 229920006393 polyether sulfone Polymers 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 238000000926 separation method Methods 0.000 description 12
• 239000003570 air Substances 0.000 description 11
• 229940126534 drug product Drugs 0.000 description 11
• 238000000265 homogenisation Methods 0.000 description 11
• 102000004196 processed proteins & peptides Human genes 0.000 description 11
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
• 238000002835 absorbance Methods 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 239000012530 fluid Substances 0.000 description 10
• 239000011148 porous material Substances 0.000 description 10
• 238000001556 precipitation Methods 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• 238000010257 thawing Methods 0.000 description 10
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
• 150000001875 compounds Chemical class 0.000 description 9
• 239000012153 distilled water Substances 0.000 description 9
• 150000002148 esters Chemical class 0.000 description 9
• 239000002245 particle Substances 0.000 description 9
• 239000002244 precipitate Substances 0.000 description 9
• 230000000717 retained effect Effects 0.000 description 9
• 239000011550 stock solution Substances 0.000 description 9
• 210000004885 white matter Anatomy 0.000 description 9
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 230000000295 complement effect Effects 0.000 description 8
• 230000007423 decrease Effects 0.000 description 8
• 239000011521 glass Substances 0.000 description 8
• 210000004408 hybridoma Anatomy 0.000 description 8
• 239000011347 resin Substances 0.000 description 8
• 229920005989 resin Polymers 0.000 description 8
• 235000000346 sugar Nutrition 0.000 description 8
• 238000012546 transfer Methods 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• 230000000996 additive effect Effects 0.000 description 7
• 210000003969 blast cell Anatomy 0.000 description 7
• 230000007717 exclusion Effects 0.000 description 7
• 238000000605 extraction Methods 0.000 description 7
• 239000000706 filtrate Substances 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 229920002521 macromolecule Polymers 0.000 description 7
• 230000014759 maintenance of location Effects 0.000 description 7
• 229920001184 polypeptide Polymers 0.000 description 7
• 229910000162 sodium phosphate Inorganic materials 0.000 description 7
• 235000011008 sodium phosphates Nutrition 0.000 description 7
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
• 238000000870 ultraviolet spectroscopy Methods 0.000 description 7
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 6
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 102100032341 PCNA-interacting partner Human genes 0.000 description 6
• 101710196737 PCNA-interacting partner Proteins 0.000 description 6
• 108700012920 TNF Proteins 0.000 description 6
• 238000004925 denaturation Methods 0.000 description 6
• 230000036425 denaturation Effects 0.000 description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
• 229910000397 disodium phosphate Inorganic materials 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 230000014509 gene expression Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 150000002500 ions Chemical class 0.000 description 6
• 230000007774 longterm Effects 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 102000039446 nucleic acids Human genes 0.000 description 6
• 108020004707 nucleic acids Proteins 0.000 description 6
• 150000007523 nucleic acids Chemical class 0.000 description 6
• 230000003287 optical effect Effects 0.000 description 6
• 230000001681 protective effect Effects 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 230000029058 respiratory gaseous exchange Effects 0.000 description 6
• 239000012465 retentate Substances 0.000 description 6
• 239000001488 sodium phosphate Substances 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 238000011179 visual inspection Methods 0.000 description 6
• 241000283073 Equus caballus Species 0.000 description 5
• 102000008100 Human Serum Albumin Human genes 0.000 description 5
• 108091006905 Human Serum Albumin Proteins 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 206010036790 Productive cough Diseases 0.000 description 5
• 238000004364 calculation method Methods 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 230000009977 dual effect Effects 0.000 description 5
• 210000002308 embryonic cell Anatomy 0.000 description 5
• 238000011156 evaluation Methods 0.000 description 5
• 235000013305 food Nutrition 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
• 238000002955 isolation Methods 0.000 description 5
• 239000011777 magnesium Substances 0.000 description 5
• 235000013336 milk Nutrition 0.000 description 5
• 239000008267 milk Substances 0.000 description 5
• 210000004080 milk Anatomy 0.000 description 5
• 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 5
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
• 229920000053 polysorbate 80 Polymers 0.000 description 5
• 230000004845 protein aggregation Effects 0.000 description 5
• 239000012488 sample solution Substances 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 208000024794 sputum Diseases 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 230000032258 transport Effects 0.000 description 5
• 238000013060 ultrafiltration and diafiltration Methods 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 238000012369 In process control Methods 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 108010025020 Nerve Growth Factor Proteins 0.000 description 4
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
• 101710166307 Protein lines Proteins 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 125000000539 amino acid group Chemical group 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 238000005341 cation exchange Methods 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 235000015165 citric acid Nutrition 0.000 description 4
• 238000007865 diluting Methods 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 238000010965 in-process control Methods 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 239000006199 nebulizer Substances 0.000 description 4
• 238000011022 operating instruction Methods 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 230000006798 recombination Effects 0.000 description 4
• 238000005215 recombination Methods 0.000 description 4
• 230000000241 respiratory effect Effects 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 229910052938 sodium sulfate Inorganic materials 0.000 description 4
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
• 235000011152 sodium sulphate Nutrition 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 230000005653 Brownian motion process Effects 0.000 description 3
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
• LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 108010000912 Egg Proteins Proteins 0.000 description 3
• 102000002322 Egg Proteins Human genes 0.000 description 3
• CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 3
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 3
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 102000007072 Nerve Growth Factors Human genes 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 239000001888 Peptone Substances 0.000 description 3
• 108010080698 Peptones Proteins 0.000 description 3
• 229920005654 Sephadex Polymers 0.000 description 3
• 239000012507 Sephadex™ Substances 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 3
• 125000003275 alpha amino acid group Chemical group 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 238000005537 brownian motion Methods 0.000 description 3
• 239000000337 buffer salt Substances 0.000 description 3
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 238000011035 continuous diafiltration Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
• 239000008367 deionised water Substances 0.000 description 3
• 229910021641 deionized water Inorganic materials 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• 239000013020 final formulation Substances 0.000 description 3
• 239000007789 gas Substances 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 102000054751 human RUNX1T1 Human genes 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 230000009878 intermolecular interaction Effects 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000012669 liquid formulation Substances 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• 238000007254 oxidation reaction Methods 0.000 description 3
• 150000002923 oximes Chemical class 0.000 description 3
• 235000019319 peptone Nutrition 0.000 description 3
• 229920001993 poloxamer 188 Polymers 0.000 description 3
• 229940044519 poloxamer 188 Drugs 0.000 description 3
• 229920000136 polysorbate Polymers 0.000 description 3
• 230000006920 protein precipitation Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 210000003802 sputum Anatomy 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 229960000257 tiotropium bromide Drugs 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
• YVYKOQWMJZXRRM-PUFIMZNGSA-N 3-dehydroshikimate Chemical compound O[C@@H]1C[C@H](C(O)=O)C=C(O)[C@@H]1O YVYKOQWMJZXRRM-PUFIMZNGSA-N 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
• 108010009575 CD55 Antigens Proteins 0.000 description 2
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
• SLWWJZMPHJJOPH-UHFFFAOYSA-N DHS Natural products OC1CC(C(O)=O)=CC(=O)C1O SLWWJZMPHJJOPH-UHFFFAOYSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
• 108090000394 Erythropoietin Proteins 0.000 description 2
• 102000003951 Erythropoietin Human genes 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 108010000521 Human Growth Hormone Proteins 0.000 description 2
• 102000002265 Human Growth Hormone Human genes 0.000 description 2
• 239000000854 Human Growth Hormone Substances 0.000 description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 238000013494 PH determination Methods 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 108010001014 Plasminogen Activators Proteins 0.000 description 2
• 102000001938 Plasminogen Activators Human genes 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 241000276498 Pollachius virens Species 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 239000004721 Polyphenylene oxide Substances 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 description 2
• 206010038743 Restlessness Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 150000005215 alkyl ethers Chemical class 0.000 description 2
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 238000000149 argon plasma sintering Methods 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000008033 biological extinction Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 229940112869 bone morphogenetic protein Drugs 0.000 description 2
• 229940094657 botulinum toxin type a Drugs 0.000 description 2
• 239000012482 calibration solution Substances 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 238000005277 cation exchange chromatography Methods 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000007979 citrate buffer Substances 0.000 description 2
• 238000005097 cold rolling Methods 0.000 description 2
• 238000012885 constant function Methods 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000013583 drug formulation Substances 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• 229940125532 enzyme inhibitor Drugs 0.000 description 2
• 229940105423 erythropoietin Drugs 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000010855 food raising agent Nutrition 0.000 description 2
• 239000001530 fumaric acid Substances 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 235000011167 hydrochloric acid Nutrition 0.000 description 2
• HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000002637 immunotoxin Effects 0.000 description 2
• 239000002596 immunotoxin Substances 0.000 description 2
• 231100000608 immunotoxin Toxicity 0.000 description 2
• 229940051026 immunotoxin Drugs 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000003434 inspiratory effect Effects 0.000 description 2
• 238000005342 ion exchange Methods 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 238000011031 large-scale manufacturing process Methods 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 239000001630 malic acid Substances 0.000 description 2
• 235000011090 malic acid Nutrition 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• YKQOSKADJPQZHB-QNPLFGSASA-N n-[(1s)-3-amino-1-{[(1s,2r)-1-{[(1s)-3-amino-1-{[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2- Chemical compound CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-QNPLFGSASA-N 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 238000010979 pH adjustment Methods 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• 229940127126 plasminogen activator Drugs 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920001983 poloxamer Polymers 0.000 description 2
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
• 239000004417 polycarbonate Substances 0.000 description 2
• 229920000570 polyether Polymers 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 239000004926 polymethyl methacrylate Substances 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 239000000473 propyl gallate Substances 0.000 description 2
• 235000010388 propyl gallate Nutrition 0.000 description 2
• 229940075579 propyl gallate Drugs 0.000 description 2
• 238000005086 pumping Methods 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 239000004627 regenerated cellulose Substances 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 238000010583 slow cooling Methods 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
• 229940001584 sodium metabisulfite Drugs 0.000 description 2
• 235000010262 sodium metabisulphite Nutrition 0.000 description 2
• 235000010265 sodium sulphite Nutrition 0.000 description 2
• 238000001179 sorption measurement Methods 0.000 description 2
• 238000002798 spectrophotometry method Methods 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 239000011975 tartaric acid Substances 0.000 description 2
• 235000002906 tartaric acid Nutrition 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• 239000002753 trypsin inhibitor Substances 0.000 description 2
• 229960005356 urokinase Drugs 0.000 description 2
• 239000000052 vinegar Substances 0.000 description 2
• 235000021419 vinegar Nutrition 0.000 description 2
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• AHJCTAYXMOPNNT-UHFFFAOYSA-N 3-hydroxy-2-phenylchromene-4-thione Chemical compound O1C2=CC=CC=C2C(=S)C(O)=C1C1=CC=CC=C1 AHJCTAYXMOPNNT-UHFFFAOYSA-N 0.000 description 1
• HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical class CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 1
• 241000208140 Acer Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
• 240000005528 Arctium lappa Species 0.000 description 1
• 235000003130 Arctium lappa Nutrition 0.000 description 1
• 235000008078 Arctium minus Nutrition 0.000 description 1
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
• 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 241001674044 Blattodea Species 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 208000031872 Body Remains Diseases 0.000 description 1
• 108030001720 Bontoxilysin Proteins 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
• 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
• 101100279436 Caenorhabditis elegans egg-2 gene Proteins 0.000 description 1
• 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
• 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
• 102400000113 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 239000002970 Calcium lactobionate Substances 0.000 description 1
• 208000003643 Callosities Diseases 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 206010068051 Chimerism Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 229920002567 Chondroitin Polymers 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 1
• 235000005979 Citrus limon Nutrition 0.000 description 1
• 244000131522 Citrus pyriformis Species 0.000 description 1
• 102100022641 Coagulation factor IX Human genes 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 240000003890 Commiphora wightii Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• MWRWFPQBGSZWNV-UHFFFAOYSA-N Dinitrosopentamethylenetetramine Chemical compound C1N2CN(N=O)CN1CN(N=O)C2 MWRWFPQBGSZWNV-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241001331845 Equus asinus x caballus Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101100400218 Escherichia coli (strain K12) lysO gene Proteins 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 102000018997 Growth Hormone Human genes 0.000 description 1
• 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 206010020649 Hyperkeratosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010021703 Indifference Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• 206010058031 Joint adhesion Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 241000735234 Ligustrum Species 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 208000032376 Lung infection Diseases 0.000 description 1
• 102000009151 Luteinizing Hormone Human genes 0.000 description 1
• 108010073521 Luteinizing Hormone Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 229920002274 Nalgene Polymers 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 241000183666 Nepsera aquatica Species 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 102100029268 Neurotrophin-3 Human genes 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 101150034459 Parpbp gene Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920002675 Polyoxyl Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
• 108010076181 Proinsulin Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 102000017975 Protein C Human genes 0.000 description 1
• 101710089165 Protein white Proteins 0.000 description 1
• 244000018633 Prunus armeniaca Species 0.000 description 1
• 235000009827 Prunus armeniaca Nutrition 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
• 108091006629 SLC13A2 Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 102100022831 Somatoliberin Human genes 0.000 description 1
• 101710142969 Somatoliberin Proteins 0.000 description 1
• 244000062793 Sorghum vulgare Species 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 101150109894 TGFA gene Proteins 0.000 description 1
• 102100033213 Teneurin-1 Human genes 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 102000011923 Thyrotropin Human genes 0.000 description 1
• 108010061174 Thyrotropin Proteins 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 229930003270 Vitamin B Natural products 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 229930003316 Vitamin D Natural products 0.000 description 1
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• CBUJHSGSOYAVJD-UHFFFAOYSA-N [2-methyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] acetate Chemical compound CC(=O)OC1=CC=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 CBUJHSGSOYAVJD-UHFFFAOYSA-N 0.000 description 1
• KKKNAENNDRVRRC-UHFFFAOYSA-N [S].OCC(O)CO Chemical compound [S].OCC(O)CO KKKNAENNDRVRRC-UHFFFAOYSA-N 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000012387 aerosolization Methods 0.000 description 1
• 229960003227 afelimomab Drugs 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000009418 agronomic effect Effects 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 239000012080 ambient air Substances 0.000 description 1
• 239000010975 amethyst Substances 0.000 description 1
• LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 230000000675 anti-caries Effects 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 229940090047 auto-injector Drugs 0.000 description 1
• WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
• 229960003644 aztreonam Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
• 238000007664 blowing Methods 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229910052796 boron Inorganic materials 0.000 description 1
• 229940053031 botulinum toxin Drugs 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000008364 bulk solution Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
• 239000001354 calcium citrate Substances 0.000 description 1
• 235000019307 calcium lactobionate Nutrition 0.000 description 1
• 229940050954 calcium lactobionate Drugs 0.000 description 1
• RHEMCSSAABKPLI-SQCCMBKESA-L calcium;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate Chemical compound [Ca+2].[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RHEMCSSAABKPLI-SQCCMBKESA-L 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 229940045200 cardioprotective agent Drugs 0.000 description 1
• 235000021466 carotenoid Nutrition 0.000 description 1
• 150000001747 carotenoids Chemical class 0.000 description 1
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 239000012578 cell culture reagent Substances 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000005660 chlorination reaction Methods 0.000 description 1
• DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 238000011210 chromatographic step Methods 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229950002334 clenoliximab Drugs 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000005515 coenzyme Substances 0.000 description 1
• 238000001246 colloidal dispersion Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 239000012468 concentrated sample Substances 0.000 description 1
• 229920002770 condensed tannin Polymers 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 239000008358 core component Substances 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 229960002433 cysteine Drugs 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000001739 density measurement Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000012738 dissolution medium Substances 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
• 238000010889 donnan-equilibrium Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 229960001484 edetic acid Drugs 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000002969 egg yolk Anatomy 0.000 description 1
• 235000013345 egg yolk Nutrition 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 230000005611 electricity Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 229940057975 ethyl citrate Drugs 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 235000019581 fat taste sensations Nutrition 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 239000012526 feed medium Substances 0.000 description 1
• 239000011790 ferrous sulphate Substances 0.000 description 1
• 235000003891 ferrous sulphate Nutrition 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000005429 filling process Methods 0.000 description 1
• 229930003935 flavonoid Natural products 0.000 description 1
• 150000002215 flavonoids Chemical class 0.000 description 1
• 235000017173 flavonoids Nutrition 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 229960000289 fluticasone propionate Drugs 0.000 description 1
• WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 229940028334 follicle stimulating hormone Drugs 0.000 description 1
• 239000012537 formulation buffer Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 239000003517 fume Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229950001109 galiximab Drugs 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229940074391 gallic acid Drugs 0.000 description 1
• 235000004515 gallic acid Nutrition 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 238000003500 gene array Methods 0.000 description 1
• 210000002980 germ line cell Anatomy 0.000 description 1
• 102000034238 globular proteins Human genes 0.000 description 1
• 108091005896 globular proteins Proteins 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 229940087603 grape seed extract Drugs 0.000 description 1
• 235000002532 grape seed extract Nutrition 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 239000001307 helium Substances 0.000 description 1
• 229910052734 helium Inorganic materials 0.000 description 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 210000000003 hoof Anatomy 0.000 description 1
• 102000043959 human IL18 Human genes 0.000 description 1
• 150000002429 hydrazines Chemical class 0.000 description 1
• GBHRVZIGDIUCJB-UHFFFAOYSA-N hydrogenphosphite Chemical compound OP([O-])[O-] GBHRVZIGDIUCJB-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 229960002240 iloprost Drugs 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000003116 impacting effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
• 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000037427 ion transport Effects 0.000 description 1
• BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
• 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 229940090046 jet injector Drugs 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 229950010828 keliximab Drugs 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 239000010985 leather Substances 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
• 235000019136 lipoic acid Nutrition 0.000 description 1
• 238000013123 lung function test Methods 0.000 description 1
• 239000003580 lung surfactant Substances 0.000 description 1
• 229940040129 luteinizing hormone Drugs 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 235000006109 methionine Nutrition 0.000 description 1
• 238000004452 microanalysis Methods 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 235000019713 millet Nutrition 0.000 description 1
• 239000003595 mist Substances 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229910052762 osmium Inorganic materials 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 230000002138 osteoinductive effect Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229950007318 ozogamicin Drugs 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 229940066779 peptones Drugs 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229940068065 phytosterols Drugs 0.000 description 1
• 235000018192 pine bark supplement Nutrition 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920001992 poloxamer 407 Polymers 0.000 description 1
• 229940044476 poloxamer 407 Drugs 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 229960003764 polydatin Drugs 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• UKPBXIFLSVLDPA-UHFFFAOYSA-N propylhydrazine Chemical compound CCCNN UKPBXIFLSVLDPA-UHFFFAOYSA-N 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 239000003531 protein hydrolysate Substances 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 230000007925 protein solubilization Effects 0.000 description 1
• 238000001799 protein solubilization Methods 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• 229940106796 pycnogenol Drugs 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 239000010453 quartz Substances 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 238000001223 reverse osmosis Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 229910052707 ruthenium Inorganic materials 0.000 description 1
• HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 238000013341 scale-up Methods 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 235000015170 shellfish Nutrition 0.000 description 1
• 230000037384 skin absorption Effects 0.000 description 1
• 231100000274 skin absorption Toxicity 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010378 sodium ascorbate Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
• 229960005055 sodium ascorbate Drugs 0.000 description 1
• 235000011083 sodium citrates Nutrition 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
• 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 229910052979 sodium sulfide Inorganic materials 0.000 description 1
• GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
• PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
• DFIWJEVKLWMZBI-UHFFFAOYSA-M sodium;dihydrogen phosphate;phosphoric acid Chemical compound [Na+].OP(O)(O)=O.OP(O)([O-])=O DFIWJEVKLWMZBI-UHFFFAOYSA-M 0.000 description 1
• IBUIVNCCBFLEJL-UHFFFAOYSA-M sodium;phosphoric acid;chloride Chemical compound [Na+].[Cl-].OP(O)(O)=O IBUIVNCCBFLEJL-UHFFFAOYSA-M 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 239000012086 standard solution Substances 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 238000010025 steaming Methods 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000004575 stone Substances 0.000 description 1
• 229940014800 succinic anhydride Drugs 0.000 description 1
• DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 229960002663 thioctic acid Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 229940042585 tocopherol acetate Drugs 0.000 description 1
• 239000003860 topical agent Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 235000013337 tricalcium citrate Nutrition 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• 238000010977 unit operation Methods 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 238000009834 vaporization Methods 0.000 description 1
• 230000008016 vaporization Effects 0.000 description 1
• 229940105295 ventavis Drugs 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 235000019166 vitamin D Nutrition 0.000 description 1
• 239000011710 vitamin D Substances 0.000 description 1
• 150000003710 vitamin D derivatives Chemical class 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 229940046008 vitamin d Drugs 0.000 description 1
• 239000001717 vitis vinifera seed extract Substances 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1